Powered by


The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg

  • Article - 30-Jun-2014

    A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early detection of chronic diseases.

  • Article - 30-Jun-2014

    Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer diagnosis.

  • Dossier - 02-Jun-2014

    Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind that although this leads to an expansion of knowledge the truth is only temporary.

  • Article - 02-Jun-2014

    Spectroscopic methods have been used for many decades in scientific research to obtain a wealth of information about chemical substances, substance mixtures and their reaction processes. Micro-biolytics GmbH from Esslingen have successfully developed a spectroscopic method that combines innovative technologies. The method enables the highly accurate and sensitive measurement of aqueous samples.

  • Press release - 27-May-2014

    Comprehensive genome analyses of cancer cells have shown that each tumor and cancer patient are unique and need to be treated individually. To pave the way, by 2015 the National Center for Tumor Diseases (NCT) Heidelberg aims to offer cancer patients at the NCT analyses of their individual cancer genomes to be used as the basis for personalized recommendations for treatment. This initiative from the DKFZ and NCT has been made possible by generous support from the Dietmar Hopp Foundation. The long-term goal is to facilitate the transition of research findings into applications and thus make individualized cancer treatment a part of standard clinical care. Leading technology companies including SAP, Molecular Health and GATC Biotech are collaborating in the project.

  • Article - 28-Apr-2014

    Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of antibodies. In addition, Sciomics produces and markets microarrays that are adapted to the specific research issues of its customers.

  • Article - 07-Apr-2014

    BIPSO GmbH, based in Singen, Germany, has been manufacturing contrast agents for applications in modern medical diagnostics since 2011. BIPSO is part of the Bracco Imaging Group, which is one of the world’s leading specialists in the diagnostic imaging business, and produces imaging agents mainly for Bracco’s sales organisations. The company has recently invested in the expansion of its manufacturing site in Singen with the goal of consolidating its leading position both now and in the future.

  • Article - 31-Mar-2014

    TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug effects and costs.

  • Article - 24-Mar-2014

    Watson and Crick deciphered the structure of DNA around 60 years ago and thus provided the key to understanding how genetic information is passed on. Since this discovery, which laid the foundation for molecular biology, new insights and developments have significantly changed many research areas and have also found their way into our everyday lives. DNA sequencing, genetic fingerprinting or personalised medicine – Watson and Crick’s heritage is omnipresent.

  • Article - 24-Mar-2014

    Hain Lifescience GmbH is a biotechnology company that develops, manufactures and distributes molecular genetic test systems and instruments. The company was established by brothers David and Tobias Hain in 1988 and employs over 100 people at its headquarters in the city of Nehren in the district of Tübingen. Hain Lifescience also has four subsidiaries abroad. The company focusses on the development of test systems for the early and rapid identification of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), which is the major cause of hospital-acquired infections. The company’s MRSA test provides a reliable result in less than three hours, enabling appropriate therapeutic measures to be taken rapidly.

  • Press release - 10-Mar-2014

    Tuebingen, March 7th 2014 – Today Saskia Biskup, co-founder and Managing Director of CeGaT GmbH, was announced as winner of the 2014 EU Prize for Women Innovators by the European Commission. The official celebration will take place in Brussels on Monday. The winners will receive their prizes from the President of the European Commission José Manuel Barroso at the opening ceremony of the Innovation Convention 2014, Europe’s premier innovation event. Saskia Biskup receives the prize for achieving outstanding innovations and bringing them to market.

  • Article - 17-Feb-2014

    CeGaT GmbH Center for Genomics and Transcriptomics in Tübingen is one of the first organisations that have managed to combine human genetic diagnostics with high-throughput sequencing for the diagnosis of specific tumour variants. CeGat researchers have developed diagnostic panels that they use to study more than 550 tumour-relevant genes simultaneously. The identification of genetic changes provides a more detailed diagnosis of tumours and helps doctors adapt therapy to the individual requirements of their cancer patients.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/diagnostics/?block_75783size=12&block_75783from=72